OWLT
Owlet, Inc.
OWLT
Owlet, Inc.
Owlet remains a buy despite flat stock performance, supported by strong Q2 results and ongoing business evolution. Q2 revenue hit a record $33.9M (up 29.9% YoY), with gross margin rebounding to 54% an
Owlet, Inc. offers the only FDA-approved wearable infant monitor, leveraging patents and data to build a subscription-based telehealth platform. OWLT's pivot to a recurring subscription model targets
Owlet NYSE: OWLT reported record second-quarter revenue as growth in its connected baby-monitoring products, international markets and subscription business helped offset promotional pressure in the c
Owlet, Inc. (OWLT) Q2 2026 Earnings Call Transcript